Status:

COMPLETED

Molecular Breast Imaging (MBI) in Patients With Suspected Ductal Carcinoma in Situ (DCIS)

Lead Sponsor:

Mayo Clinic

Conditions:

Breast Cancer

Eligibility:

FEMALE

25-90 years

Brief Summary

In this research study, the investigators are testing a new type of breast camera, called Molecular Breast Imaging, to see if it can find tumors in the subject's breast.

Detailed Description

Patients who are suspected to have DCIS based on mammographic findings will be invited to participate in this study. The investigators plan to recruit 200 patients who are scheduled to undergo a breas...

Eligibility Criteria

Inclusion

  • Women with a breast lesion suspicious for DCIS who are scheduled for a stereotactic breast biopsy.
  • Lesion must be considered suggestive or highly suggestive of malignancy according to the Breast Imaging Reporting and Data System Atlas criteria (BIRADS 4 or 5).
  • Women between 25 and 90 years of age.

Exclusion

  • Unable to understand or sign a consent form.
  • Pregnant or lactating.
  • Physically unable to sit upright and still for 30-40 minutes.

Key Trial Info

Start Date :

January 19 2009

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

November 14 2016

Estimated Enrollment :

200 Patients enrolled

Trial Details

Trial ID

NCT00890994

Start Date

January 19 2009

End Date

November 14 2016

Last Update

March 22 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Mayo Clinic

Rochester, Minnesota, United States, 55905

Molecular Breast Imaging (MBI) in Patients With Suspected Ductal Carcinoma in Situ (DCIS) | DecenTrialz